The Bacterial Strain that Babies Need: *B. infantis* EVC001

The Right Bacteria | Specifically adapted to the infant gut

- The term probiotic is general; bacteria vary widely in terms of function and mechanism
- *B. infantis* is specifically adapted to colonize the infant gut[1]

The Right Food | Utilizes breast milk

- Infants have a single source of nutrition during the first six months of life
- 15% of nutrients in breast milk Human Milk Oligosaccharides (HMOs) require digestion by *B. infantis*
- *B. infantis* EVC001 is the only probiotic bacteria that metabolizes the complete array of HMOs[1]

The Right Time | The first 6 months of life

- The first 6 months of life include rapid growth, development, and immune programming
- The gut microbiome is critical for immune system development, with long-term health implications
- *B. infantis* EVC001 is clinically shown to reduce gut pathogens, reduce intestinal inflammation in infants during the crucial window of immune development[3, 5, 8]

The Right Strain | Clinically proven to benefit the infant gut

- Only *B. infantis* EVC001 is clinically studied with peer-reviewed data for safety and functional, measurable benefit to the infant gut[2-8]
- *B. infantis* EVC001 is the only infant probiotic strain to rapidly colonize the infant gut, reduce gut pathogens, and resolve gut dysbiosis[3, 5]

EVIVO®

www.Evivo.com

The only probiotic strain clinically proven to benefit the infant gut

B. infantis EVC001 leads the way with peer-reviewed studies

	B. infantis Strain (Brand)				
	EVC001 (Evivo®)	NLS (Natren)	HA-116 (Udo's Choice)	PXN®27™ (BioKult Infants)	BB02® (Chr. Hansen)
Grows on HMOs[1]	+	-	-	-	-
Reduces Gut Pathogens[5]	+	-	-	-	-
Protects Intestinal Mucous Layer[6]	+	-	-	-	-
Reduces Intestinal Inflammation[8]	+	-	-	-	-
Reduces Antibiotic Resistance[7]	+	-	-	-	-

QUALITY AND MANUFACTURING FOR INFANTS

- Full ownership and control of bacterial strain
- Product produced in high-quality, regularly FDA-inspected facility
- Single-use, ready-to-use
- Cold shipped supply chain
- Demonstrated and published safety and tolerability review in infants;[2] successfully completed GRAS evaluation

Protect your patients with the clinically proven power of Evivo.

Visit Samples.Evivo.com
for more information or to order samples today

About Evolve BioSystems

Evolve BioSystems, Inc. is a microbiome company dedicated to solving infant gut dysbiosis. Founded out of the University of California, Davis, Evolve is a portfolio company of the Bill & Melinda Gates Foundation and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and human breast milk.

Scan for more information on clinical studies on Evivo.

1. Sela, D. A., et al. "The genome sequence of *Bifidobacterium longum* subsp. *infantis* reveals adaptations for milk utilization within the infant microbiome." *Proceedings of the National Academy of Sciences* 105.48 (2008): 18964-18969.
2. Smilowitz, Jennifer T., et al. "Safety and tolerability of *Bifidobacterium longum* subspecies *infantis* EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial." *BMC Pediatrics* 17.1 (2017): 133.
3. Frese, Steven A., et al. "Persistence of Supplemented *Bifidobacterium longum* subsp. *infantis* EVC001 in Breastfed Infants." *MSphere* 2.6 (2017): e00501-17.
4. Henrick, Bethany M., et al. "Elevated fecal pH indicates a profound change in the breastfed infant gut microbiome due to reduction of *Bifidobacterium* over the past century." *MSphere* 3.2 (2018): e00041-18.
5. Casaburi, Giorgio, and Steven A. Frese. "Colonization of breastfed infants by *Bifidobacterium longum* subsp. *infantis* EVC001 reduces virulence gene abundance." *Human Microbiome Journal* 9 (2018): 7-10.
6. Karav, Sercan, Giorgio Casaburi, and Steven A. Frese. "Reduced colonic mucin degradation in breastfed infants colonized by *Bifidobacterium longum* subsp. *infantis* EVC001." *FEBS* open bio 8.10 (2018): 1649-1657.
7. Casaburi, Giorgio, et al. "Early-life gut microbiome modulation reduces the abundance of antibiotic-resistant bacteria." *Antimicrobial Resistance & Infection Control* 8.1 (2019): 131.
8. Henrick, Bethany M., et al. "Colonization by *B. infantis* EVC001 modulates enteric inflammation in exclusively breastfed infants." *Pediatric Research* (2019): 1-9.